The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years' experience of a single center
Abstract Background Myelodysplastic syndrome (MDS) is a rare disease in children and the treatment option before the allogeneic hematopoietic stem cell transplantation (allo-HSCT) is rarely reported. Our main objective was to report our single-center experience with the DNA-hypomethylating agent, de...
Saved in:
Main Authors: | Junyan Gao (Author), Yixin Hu (Author), Li Gao (Author), Peifang Xiao (Author), Jun Lu (Author), Shaoyan Hu (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Autoimmune complication post HSCT in a case of MDS with monosomy 7
by: Zainab M. Golwala, et al.
Published: (2017) -
Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
by: Bu X, et al.
Published: (2023) -
What after MDS?
by: Vijay Deshmukh
Published: (2014) -
Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia
by: Ashkan Emadi, et al.
Published: (2016) -
Why not MDS in dental material sciences?
by: Vijay Deshmukh
Published: (2016)